Cargando…
Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance
In this pilot clinical trial, we evaluated rates of residual replication in persons without lamivudine resistance-associated mutations in proviral DNA population sequencing who switched to dolutegravir plus lamivudine. After 144 weeks, there was no signal of changes in residual viremia based on qual...
Autores principales: | De Miguel Buckley, Rosa, Rial-Crestelo, David, Montejano, Rocío, Pinto, Adriana, Jimenez-Gonzalez, María, Lagarde, Maria, Esteban-Cantos, Andrés, Aranguren-Rivas, Paula, Cadiñanos, Julen, Bisbal, Otilia, Castro, Juan Miguel, Santacreu-Guerrero, Mireia, Bermejo-Plaza, Laura, Moreno, Victoria, Hernando, Asunción, Martín-Carbonero, Luz, Rubio, Rafael, Delgado, Rafael, Arribas, José Ramón, Pulido, Federico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697602/ https://www.ncbi.nlm.nih.gov/pubmed/36447613 http://dx.doi.org/10.1093/ofid/ofac610 |
Ejemplares similares
-
Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)
por: De Miguel, Rosa, et al.
Publicado: (2020) -
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
por: Suárez-García, Inés, et al.
Publicado: (2023) -
No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial
por: Li, Jonathan Z, et al.
Publicado: (2019) -
Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
por: Zamora, Francis J, et al.
Publicado: (2019) -
Real-World Effectiveness, Tolerability, and Safety of Dolutegravir/Lamivudine in Korea
por: Lee, Ki Hyun, et al.
Publicado: (2022)